A controversial company that sells license plate readers has developed a new surveillance tool that pulls together disparate datasets and connects them to drivers’ car information.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

The House Energy and Commerce Committee is launching a new probe into DeepSeek, whether it shares data with the CCP and is trained to give answers to align with Chinese propaganda.

Recursion will present preliminary safety and efficacy data for REC-4881 in familial adenomatous polyposis at DDW 2025. Quiver AI Summary. Recursion, a clinical-stage TechBio company, is set to ...

Recursion Pharma’s May update is the primary near-term driver of its stock. The company ended 2024 with $60M in cash, providing runway till 2027. 9 Out of the Last 10 Summers this "Power Pattern ...

Using Chunk to process large files in C# Chunking is beneficial whenever you’re handling large data sets or massive volumes of data. Chunking also comes in handy when processing large files ...

The Data Science Lab. Decision Tree Regression from Scratch Using C#. Dr. James McCaffrey from Microsoft Research presents a complete end-to-end demonstration of decision tree regression using the C# ...

Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger Recursion is working on 10 potential drugs, and has enough cash to fuel itself through 2027 Manage ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI ...

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...